Opdivo and Halcion drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Opdivo (nivolumab) and Halcion (triazolam). Common drug interactions include erythema among females and rhabdomyolysis among males.

The phase IV clinical study analyzes what interactions people have when they take Opdivo and Halcion. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Halcion?

Halcion has active ingredients of triazolam. It is often used in insomnia. eHealthMe is studying from 8,268 Halcion users. Check the latest studies of Halcion.

On Jul, 17, 2026

19 people who take Opdivo and Halcion together, and have interactions are studied.

What are the common drug interactions of Opdivo and Halcion, by gender? *:

female:

Erythema (redness of the skin)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
Asthenia (weakness)
Hepatotoxicity (chemical-driven liver damage)
Hypophysitis (inflammation of the pituitary gland)
Upper limb fracture
Cardiac amyloidosis (protein deposition in heart)
Anaemia (lack of blood)
Facial paralysis (loss of function of face muscle)

male:

Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Erysipelas (bacterial skin infection)
Performance status decreased
Pulmonary toxicity (side effects on the lungs)
Hypophysitis (inflammation of the pituitary gland)
Cholangitis sclerosing (infection and obstruction of bile duct)
Blood thyroid stimulating hormone decreased
Secondary adrenocortical insufficiency (inadequate secretion of acth by the pituitary gland)
Thyroiditis (inflammation of thyroid gland)
Type 1 diabetes mellitus

What are the common drug interactions of Opdivo and Halcion, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Hypophysitis (inflammation of the pituitary gland)
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Interstitial lung disease
Secondary adrenocortical insufficiency (inadequate secretion of acth by the pituitary gland)
Thyroiditis (inflammation of thyroid gland)
Type 1 diabetes mellitus
Upper limb fracture
Cardiac amyloidosis (protein deposition in heart)
Anaemia (lack of blood)
Facial paralysis (loss of function of face muscle)

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 9 people, 47.37%
Oral Cancer (mouth cancer): 4 people, 21.05%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 10.53%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 10.53%
High Blood Pressure: 2 people, 10.53%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 1 person, 5.26%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 1 person, 5.26%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 5.26%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 5.26%
Diabetes: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and Halcion?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously